Lexicon Pharmaceuticals, Inc. (LX31)
XBER 
Summary
LX31 Chart
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Lexicon Pharmaceuticals, Inc. ( LXRX ) Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM EST Company Participants Michael Exton - CEO & Director Craig Granowitz - Senior VP & Chief Medical Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Presentation Lin Tsai Jefferies LLC, Research Division Thank you, everyone, for tuning in. I'm Andrew Tsai, Senior biotech analyst at Jefferies, and it's my pleasure to have the Lexicon team with me today.
Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win
Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval in Type 1 diabetes and hypertrophic cardiomyopathy, but new data and ongoing trials offer near-term catalysts. Novo Nordisk partnership on LX9851 and improved pilavapadin data provide financial support and partnership credibility, helping LXRX regain Nasdaq compliance.
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2025 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. ( LXRX ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Lisa DeFrancesco - Senior Vice President of Investor Relations & Corporate Communications Michael Exton - CEO & Director Craig Granowitz - Senior VP & Chief Medical Officer Scott Coiante - Senior VP & CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Welcome to the Lexicon Pharmaceuticals Third Quarter 2025 Financial Results Conference Call.
Lexicon Pharmaceuticals, Inc. (LX31) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Lexicon Pharmaceuticals, Inc. ever had a stock split?
Lexicon Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael S. Exton CEO | XBER Exchange | US5288723027 ISIN |
| US Country | 103 Employees | - Last Dividend | 21 May 2015 Last Split | 7 Apr 2000 IPO Date |
Overview
Lexicon Pharmaceuticals, Inc. is a pioneering biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative pharmaceutical products. Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals has emerged as a leader in its field, primarily focusing on orally-delivered small molecule drug candidates. The company has established strategic collaboration and license agreements with industry giants such as Bristol-Myers Squibb Company and Genentech, Inc., which facilitate the advancement of its research and development efforts in creating life-changing therapies for patients worldwide.
Products and Services
- Sotagliflozin
An orally-delivered small molecule drug that has successfully completed Phase III clinical trials, Sotagliflozin is at the forefront of Lexicon Pharmaceuticals' promising pipeline. This innovative drug candidate is primarily targeted for the treatment of heart failure and type 1 diabetes, offering a new hope for patients suffering from these chronic conditions through its novel mechanism of action and potential benefits.
- LX9211
Currently in Phase II clinical development, LX9211 represents another key component of the company's robust portfolio. Designed to address the crippling effects of neuropathic pain, LX9211 aims to alleviate suffering and improve the quality of life for patients battling this challenging condition. Its progression into Phase II trials underscores Lexicon Pharmaceuticals' commitment to targeting and treating complex pain syndromes with cutting-edge science and therapeutics.
- LX2761
A promising candidate in the early stages of clinical development, LX2761 is in Phase I trials with a focus on the treatment of issues affecting the gastrointestinal tract. This drug exemplifies Lexicon Pharmaceuticals' strategic exploration into novel therapeutic areas, leveraging its expertise in small molecule drug development to potentially offer new solutions for digestive health complications.
Contact Information
